- ISIN
- US24823R1059
- CUSIP
- 24823R105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 8, 2017
Highlights
- Market Cap
- $4.49B
- Enterprise Value
- $4.13B
- EPS (TTM)
- -$2.88
- Gross Profit (TTM)
- -$2.87M
- EBITDA (TTM)
- -$526.60M
- Year Range
- $12.58 - $24.65
- Target Price
- $34.50
- ROA (TTM)
- -40.13%
- ROE (TTM)
- -54.86%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DNLI Performance Chart
Denali Therapeutics Inc. (DNLI) is up 45.7% since the beginning of the year. At $24 per share, DNLI is trading just below its 52-week high of $25. Investors who bought $1,000 worth of DNLI shares 5 years ago would now be looking at an investment worth $339.
Loading charts...
Returns By Period
Denali Therapeutics Inc. (DNLI) has returned 45.67% so far this year and 73.15% over the past 12 months.
Denali Therapeutics Inc.
- 1D
- 3.17%
- 1M
- 29.02%
- YTD
- 45.67%
- 6M
- 37.66%
- 1Y
- 73.15%
- 3Y*
- -5.96%
- 5Y*
- -19.47%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
DNLI Monthly Returns History
Based on dividend-adjusted daily data since Dec 8, 2017, DNLI's average daily return is +0.09%, while the average monthly return is +1.73%. At this rate, an investment would double in approximately 3.4 years.
Historically, 50% of months were positive and 50% were negative. The best month was Aug 2018 with a return of +55.9%, while the worst month was Jul 2021 at -34.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, DNLI closed higher 48% of trading days. The best single day was Feb 27, 2024 with a return of +38.3%, while the worst single day was Jan 4, 2021 at -15.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 31.68% | -2.58% | -9.35% | -2.50% | 12.39% | 14.31% | 45.67% | ||||||
| 2025 | 14.33% | -28.93% | -17.90% | 22.47% | -20.48% | 5.66% | -1.14% | 10.41% | -4.91% | 12.12% | 19.59% | -15.20% | -18.99% |
| 2024 | -25.40% | 23.55% | 3.74% | -24.76% | 20.21% | 25.11% | 4.95% | 0.29% | 19.19% | -10.88% | -3.70% | -18.48% | -5.03% |
| 2023 | 8.85% | -10.31% | -15.14% | 7.81% | 21.66% | -2.35% | -3.66% | -18.78% | -10.65% | -8.73% | -1.65% | 15.87% | -22.83% |
| 2022 | -23.27% | -4.85% | -1.20% | -26.02% | 2.06% | 21.16% | 15.60% | -18.67% | 10.91% | -6.55% | 11.26% | -12.85% | -37.65% |
| 2021 | -18.22% | 4.82% | -20.47% | 5.85% | 5.21% | 23.35% | -34.94% | 4.25% | -5.17% | -4.16% | -4.32% | -3.59% | -46.75% |
Benchmark Metrics
Denali Therapeutics Inc. has an annualized alpha of 2.75%, beta of 1.37, and R2 of 0.16 versus S&P 500 Index. Calculated based on daily prices since December 08, 2017.
- This stock participated in 165.66% of S&P 500 Index downside but only 140.13% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.16 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 2.75%
- Beta
- 1.37
- R²
- 0.16
- Upside Capture
- 140.13%
- Downside Capture
- 165.66%
Return for Risk
Risk / Return Rank
DNLI ranks 79 for risk / return — better than 79% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Denali Therapeutics Inc. (DNLI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DNLI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.74 | ||
| Sortino ratioReturn per unit of downside risk | -0.79 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.37 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 3.59 | 2.78 | +0.80 |
| Martin ratioReturn relative to average drawdown | 7.12 | 12.44 | -5.32 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Denali Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Denali Therapeutics Inc. was 87.74%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Denali Therapeutics Inc. drawdown is 74.29%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -87.74%Apr 2025 | 4y 3mo | — | 5y 6moDec 2020 - now |
2018 bear market2018 | -49.76%Jul 2018 | 5mo 10d | 8mo 6d | 1y 1moFeb 2018 - Apr 2019 |
COVID crash2020 | -49.54%Mar 2020 | 11mo 10d | 2mo 18d | 1y 1moApr 2019 - Jun 2020 |
2017 bear market2017 | -30.21%Dec 2017 | 20d | 25d | 1mo 15dDec 2017 - Jan 2018 |
2020 correction2020 | -19.74%Jul 2020 | 1mo 20d | 13d | 2mo 3dJun 2020 - Aug 2020 |
Drawdown Indicators
| DNLI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.74% | -56.78% | -30.96% |
Max Drawdown (1Y)Largest decline over 1 year | -20.49% | -9.10% | -11.39% |
Max Drawdown (3Y)Largest decline over 3 years | -63.68% | -18.90% | -44.78% |
Max Drawdown (5Y)Largest decline over 5 years | -85.38% | -25.43% | -59.95% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -74.29% | -1.80% | -72.49% |
Average DrawdownAverage peak-to-trough decline | -51.60% | -10.71% | -40.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.31% | 2.03% | +8.28% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Denali Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Denali Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DNLI in comparison with other companies in the Biotechnology industry. Currently, DNLI has a P/B value of 4.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DNLI
Add Denali Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DNLI